US3784684A - Coronary dilator in a pharmaceutical dosage unit form - Google Patents

Coronary dilator in a pharmaceutical dosage unit form Download PDF

Info

Publication number
US3784684A
US3784684A US00282476A US3784684DA US3784684A US 3784684 A US3784684 A US 3784684A US 00282476 A US00282476 A US 00282476A US 3784684D A US3784684D A US 3784684DA US 3784684 A US3784684 A US 3784684A
Authority
US
United States
Prior art keywords
parts
weight
shell
gelatine
dihydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00282476A
Other languages
English (en)
Inventor
F Bossert
W Vater
K Bauer
K Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25761638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US3784684(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19722209526 external-priority patent/DE2209526C3/de
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of US3784684A publication Critical patent/US3784684A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S206/00—Special receptacle or package
    • Y10S206/828—Medicinal content

Definitions

  • the present invention relates to a new dosage unit form I for a known coronary dilator, 4-(2-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine, and a method for its production. See US. Pats. 3,485,847; 3,644,627; and Canadian Pats. 868,909; 868,910; 868,911.
  • Disturbances of the coronary blood flow resembling an attack and manifesting themselves clinically in the form of a so-called angina pectoris attack are a vitally important indication and demand immediate treatment with a drug.
  • An attack of angina pectoris is usually accompanied by intolerable pain and feelings of extreme anxiety. Physiologically, the impaired blood flow through the heart during an attack can result in permanent damage to the cardiac muscle which in an extreme case can lead to death. Drugs which are employed in the therapy of angina pectoris must therefore become fully efliective in the shortest possible time (within a few minutes).
  • 1,4-dihydropyridine derivatives act as coronary dilators and can be used in the treatment Patented Jan, 8, 1974 of the above disease. Substances which belong to this group of compounds do not dissolve readily and are extremely light-sensitive.
  • So labile is the redox system of 1,4-dihydropyridines, that the addition of reducing agents, oxidizing agents, or redox systems (e.g. Fe II/Fe III, ascorbic acid/dehydroascorbic acid) cannot check rapid decomposition.
  • reducing agents e.g. Fe II/Fe III, ascorbic acid/dehydroascorbic acid
  • redox systems e.g. Fe II/Fe III, ascorbic acid/dehydroascorbic acid
  • perlingually administered drugs are rapidly absorbed and that they therefore have a rapid onset of action (e.g. nitroglycerol) (Sollman, T., A Manual of Pharmacology, W. B. Saunders Co., Philadelphia, Pa., 1957, p. 631).
  • the present invention provides an instant oral-release capsule having a shell of gelatine preferably incorporating an opacifier and a dye, said shell containing a mixture of:
  • the shell incorporates a dye that absorbs light of wavelength 250-460 nm. and an opacifier, and the mixture contains 1 to 10, preferably 5 to 8, parts by weight of the at least one alcohol.
  • a particularly preferred proportion of the at least one polyalkylene glycol in the mixture is 15 to 35 parts by weight.
  • the invention also provides a process for the production of the capsules of the invention, comprising mixing the ingredients (1) to (3) and any other ingredients, and enclosing the resultant mixture in the gelatine capsule.
  • instant oral-release capsule means a capsule, having a shell, generally of gelatine, containing a fluid pharmaceutical composition which can be released from the shell by biting and breaking the latter; the subject bites this capsule thereby releasing its contents into his mouth from where the medicament is immediately absorbed into his system.
  • Each capsule will generally contain a specific measured amount of the pharmaceutical composition which is enough for a single dose.
  • capsules according to the present invention containing 4-(2 nitrophenyl)-2,6-dimethyl-3,5-dicarbo methoxy-l,4-dihydropyridine has the following advantages: the capsule can be taken immediately by the patient himself in the event of a heart attack and takes elfect within a few minutes. There can be no doubt about the dosage, as it is fixed by the amount of active ingredient contained in the instant oral-release capsule. Administration is extremely simple: it is carried out perlingually, which dispenses with the necessity, for example, of first counting out a certain number of drops containing the active ingredient. Such procedure is impossible in the present case anyway because the active ingredient is too light-sensitive.
  • the active ingredient used in the capsules of the invention is a known compound, 4-(2-nitrophenyl)-2,6-dimethyl-3,S-dicarbomethoxy 1,4 dihydropyridine which has been administered in a variety of conventional pharmaceutical formulations including common gelatine capsules and with conventional carriers including polyalkylene glycols.
  • This compound has the formula Polyalkylene glycols having a mean molecular weight of 200 to 4000 suitable for use according to the invention are also known.
  • Polyethylene and/or polypropylene glycol having a mean molecular weight of 300 to 600 are preferably used.
  • polyglycols Hoechst
  • Lutrol 9 BASF
  • Polydiols Haills
  • Carbowaxes Union Carbide
  • Lower alcohols having 2 to 8 carbon atoms and 1 to 3 hydroxy groups suitable for use in accordance with the invention are also known.
  • Glycerol, propylene glycol, butylene glycol or benzyl alcohol are preferably used.
  • the mixture contained in the capsule may also contain one or more further ingredients apart from those specifically mentioned above.
  • auxiliary agents may be employed: flavoring agents (aromas), essential oils, preferably peppermint oil, fennel oil, anise oil, caraway oil, lemon oil or eucalyptus oil), and sweetening agents (e.g. saccharin, sodium saccharin (soluble saccharin) and glycyrrhizinic acid ammonium salt).
  • the dye incorporated into the gelatine shell of the capsule preferably absorbs light in the wavelength range 280-420 nm.
  • a preferred dye is the foodstulf dye Gelborange-S (Sunset Yellow) (Color Index No. 15 985).
  • the dye should, of course, have no toxic effect when used according to the invention.
  • a preferred opaeifier for incorporation into the gelatine shell is titanium dioxide.
  • the gelatine shell used in accordance with the invention preferably consists, in its ready-to-use state, of 54% to 80% of gelatine, 10% to 36% of glycerol or sorbitol and 7% to 15% of water and 0.5% to of an opacifier such as titanium dioxide, an iron oxide (such as yellow iron oxide, red iron oxide or brown iron oxide) or calcium carbonate, and the dye Gelborange-S (Color Index No. 15 985).
  • the gelatine composition for the capsule shell can conveniently be prepared by mixing 40% to 66% of pure gelatine with 8% to 36% of glycerol (or sorbitol) and 22% to 34% of water and by allowing the mixture to swell for some time.
  • this composi- 4 tion is melted at 60 C. until free of bubbles and the opaeifier and the dye Gelborange-S (Color Index No. 15 985) and, if desired, preservatives (e.g. p-aminobenzoic acid, sorbic acid, and benzyl alcohol) are homogeneously worked into the composition.
  • preservatives e.g. p-aminobenzoic acid, sorbic acid, and benzyl alcohol
  • the mixture constituting the filling of the capsule according to the invention is conveniently prepared by dissolving 4-(2' nitrophenyl)-2,6-dimethyl-3,S-dicarbomethoxy-l,4-dihydropyridine in the alcohol and polyalkylene glycol with slight heating and stirring.
  • the filling into the gelatine capsules can be carried out according to known methods; for example, with Scherer, Leiner, Norton or Accogel machines. After filling, the capsules are generally dried and are then ready to use.
  • the accompanying drawing is a graph showing the very rapid onset of action with perlingual absorption, in particular in comparison with oral administration of the active ingredient of the invention in tragacanth.
  • the graph illustrates the action of the active ingredient according to the invention upon administration in various ways to dogs which have been anaesthetized and catheterized in the coronary sinus.
  • the rise in oxygen pressure in the blood of the coronary veins after perlingual administration of 1 mg./kg. of the active ingredient according to the invention in the form of a mixture of glycerol, polyethylene glycol and water was recorded in comparison with the application into the stomach of 1 mg./kg. of the active ingredient (micronized substance in tragacanth)
  • the mean values are given for 5 tests each.
  • the curve clearly shows the immediate onset of action following perlingual administration. After five minutes the maximal value is almost reached, whereas after administration into the stomach the oxygen pressure only attains the same value after 60 minutes. Administration of the active ingredient in solid formulation, such as tablets, drages or the like reveals even less favorable values.
  • An instant oral-release gelatine shell perlingual capsule having a dye that absorbs light of wave lengths of from 250 to 460 nm. and an opacifier in the shell of gelatine, said shell being capable of being broken by biting, and enclosed within said shell a fluid mixture of:
  • An instant oral-release capsule according to claim 1 which contains to 35 parts by weight of said at least one polyalkylene glycol.
  • An instant oral-release capsule according to claim 1 wherein said at least one alcohol is glycerol, propylene glycol, butylene glycol, benzyl alcohol or a mixture of 2 or more thereof.
  • An instant oral-release capsule according to claim 1 wherein the opacifier is titanium dioxide, an iron oxide or calcium carbonate.
  • An instant oral-release capsule according to claim 11 wherein the iron oxide is yellow iron oxide, red iron oxide or brown iron oxide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Hydrogenated Pyridines (AREA)
US00282476A 1971-08-24 1972-08-21 Coronary dilator in a pharmaceutical dosage unit form Expired - Lifetime US3784684A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2142316 1971-08-24
DE19722209526 DE2209526C3 (de) 1972-02-29 1972-02-29 Coronartherapeutlkum in Form von Gelatine-BeiBkapseln

Publications (1)

Publication Number Publication Date
US3784684A true US3784684A (en) 1974-01-08

Family

ID=25761638

Family Applications (1)

Application Number Title Priority Date Filing Date
US00282476A Expired - Lifetime US3784684A (en) 1971-08-24 1972-08-21 Coronary dilator in a pharmaceutical dosage unit form

Country Status (25)

Country Link
US (1) US3784684A (ja)
JP (2) JPS5434048B2 (ja)
KR (1) KR780000433B1 (ja)
BE (1) BE787951A (ja)
BG (1) BG27728A3 (ja)
CA (1) CA981582A (ja)
CY (1) CY918A (ja)
DD (1) DD99729A5 (ja)
DK (1) DK130628B (ja)
EG (1) EG10633A (ja)
ES (1) ES406047A1 (ja)
FI (1) FI53922C (ja)
FR (1) FR2150848B1 (ja)
GB (1) GB1362627A (ja)
HK (1) HK44877A (ja)
IE (1) IE36891B1 (ja)
IL (1) IL40165A (ja)
KE (1) KE2756A (ja)
LU (1) LU65929A1 (ja)
MY (1) MY7800003A (ja)
NL (1) NL176836C (ja)
NO (1) NO138167C (ja)
RO (1) RO88521B (ja)
SG (1) SG34877G (ja)
SU (1) SU432703A3 (ja)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4056610A (en) * 1975-04-09 1977-11-01 Minnesota Mining And Manufacturing Company Microcapsule insecticide composition
US4088750A (en) * 1974-02-22 1978-05-09 Burroughs Wellcome Co. Method and preparation for increasing bioavailability of digoxin
DE2822882A1 (de) * 1977-06-07 1978-12-21 Yamanouchi Pharma Co Ltd Nifedipine-enthaltende feste praeparatzusammensetzung, verfahren zu ihrer herstellung und ihre verwendung
US4198391A (en) * 1973-07-20 1980-04-15 R. P. Scherer Ltd. Pharmaceutical compositions
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
WO1984003417A1 (en) * 1983-03-02 1984-09-13 Scherer Corp R P Soft gelatin capsules and fill achieving optimum hardness and flexibility during storage
US4537898A (en) * 1983-03-03 1985-08-27 Bayer Aktiengesellschaft Liquid formulations of dihydropyridines
EP0164587A2 (de) * 1984-05-23 1985-12-18 Bayer Ag Nifedipinpräparate und Verfahren zu ihrer Herstellung
EP0165450A2 (de) * 1984-05-23 1985-12-27 Bayer Ag Nifedipinkombinationspräparate und Verfahren zu ihrer Herstellung
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4689233A (en) * 1986-01-06 1987-08-25 Siegfried Aktiengesellschaft Coronary therapeutic agent in the form of soft gelatin capsules
US4693892A (en) * 1985-09-10 1987-09-15 Bayer Aktiengesellschaft Gelatin containing β-carotene
US4777048A (en) * 1983-07-07 1988-10-11 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4780316A (en) * 1983-03-02 1988-10-25 R.P. Scherer Corporation Gelatin capsule
AU584122B2 (en) * 1984-08-23 1989-05-18 Kuhlemann & Co. Metered dose aerosol of nifedipin
US4832952A (en) * 1983-07-07 1989-05-23 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4857312A (en) * 1985-12-18 1989-08-15 Bayer Aktiengesellschaft Dihydropyridine spray, process for its preparation and its pharmaceutical use
US4894235A (en) * 1984-10-23 1990-01-16 Dr. Rentschler, Arzneimmittel Gmbh & Co. Nifedipine-containing form of administration and method for its production
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US4976965A (en) * 1987-04-30 1990-12-11 Kali-Chemie Pharma Gmbh Coronary affecting medicinal composition
US5200192A (en) * 1987-11-11 1993-04-06 Walter Wimmer Instant oral-release capsule containing nifedipine
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
US5266581A (en) * 1984-07-04 1993-11-30 Bayer Aktiengesellschaft Solid composition containing dihydropyridine, PVP and PVPP
US5431916A (en) * 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
WO1997038662A2 (en) * 1996-04-12 1997-10-23 Flemington Pharmaceutical Corporation Buccal polar spray or capsule
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5846563A (en) * 1993-09-09 1998-12-08 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6093420A (en) * 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
EP1208843A1 (en) * 1999-08-31 2002-05-29 Chugai Seiyaku Kabushiki Kaisha Soft capsules
WO2002087543A1 (en) * 2001-05-01 2002-11-07 Biozone Laboratories, Inc. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030102246A1 (en) * 1999-03-20 2003-06-05 Lts Lohmann Therapie-Systeme Ag Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US6676931B2 (en) 1997-10-01 2004-01-13 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US20040120896A1 (en) * 1997-10-01 2004-06-24 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20040170684A1 (en) * 1999-09-30 2004-09-02 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs
US20040265239A1 (en) * 1997-10-01 2004-12-30 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
EP1502588A1 (en) * 2002-05-09 2005-02-02 Chugai Seiyaku Kabushiki Kaisha Light-stabilized soft capsule for formulations
US20050084457A1 (en) * 2001-06-01 2005-04-21 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20050169983A1 (en) * 2002-04-25 2005-08-04 Hassan Emadeldin M. Chewable soft capsule
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20060216241A1 (en) * 1997-10-01 2006-09-28 Novadel Pharma Inc. Buccal, polar and non-polar spray containing diazepam
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods
US20080280947A1 (en) * 2007-05-10 2008-11-13 Blondino Frank E Anti-insomnia compositions and methods
US20090107836A1 (en) * 2007-10-30 2009-04-30 Novellus Systems, Inc. Closed Contact Electroplating Cup Assembly
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20100286277A1 (en) * 2008-01-18 2010-11-11 Wurm David B Method to enhance aqueous solubility of poorly soluble actives
CN102300563A (zh) * 2009-01-29 2011-12-28 大日本住友制药株式会社 具有内核的口腔崩解片剂
CN101300010B (zh) * 2005-10-31 2012-06-06 兴和株式会社 光稳定性优异的医药制剂
US9205123B2 (en) 2010-02-23 2015-12-08 Tasly Pharmaceutical Group Co., Ltd. Capsule of compound danshen dripping pills
TWI571257B (zh) * 2011-02-23 2017-02-21 Tasly Pharmaceutical Group Co Capsule preparation
WO2019219693A1 (en) 2018-05-14 2019-11-21 Capsugel Belgium Nv Capsules with opacifier
WO2019241519A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (ja) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
ZA725808B (en) * 1971-08-24 1973-05-30 Bayer Ag A coronary agent in special form and processes for its manufacture
GB1481411A (en) * 1973-07-20 1977-07-27 Scherer Ltd R Pharmaceutical compositions
JPS52151724A (en) * 1976-06-07 1977-12-16 Takeda Chem Ind Ltd Hard shell gelatin capsule
JPS5484023A (en) * 1977-12-19 1979-07-04 Teijin Ltd Soft capsule containing active vitamin d3, and its preparation
JPS5522631A (en) * 1978-08-07 1980-02-18 Ota Seiyaku Kk Readily absorbable nifedipine preparation
JPS5522645A (en) * 1978-08-07 1980-02-18 Fujisawa Pharmaceut Co Ltd Soft capsule for encapsulation of light-unstable compound
JPS5939827A (ja) * 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
ATE33348T1 (de) * 1983-11-30 1988-04-15 Siegfried Ag Coronartherapeutikum in form von weichgelatinekapseln.
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4656028A (en) * 1986-06-24 1987-04-07 Norcliff Thayer Inc. Encapsulated antacid
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
DE3639418A1 (de) * 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
GB8629761D0 (en) * 1986-12-12 1987-01-21 Harris Pharma Ltd Capsules
EP0272336B1 (de) * 1986-12-18 1991-10-23 Kurt H. Prof. Dr. Bauer Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung
CA2056032A1 (en) * 1990-11-29 1992-05-30 Minoru Aoki Hard capsule preparation
JP4730985B2 (ja) * 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870061A (en) * 1956-11-08 1959-01-20 Mead Johnson & Co Concentrates of dialkyl sulfosuccinates
US3155587A (en) * 1963-01-23 1964-11-03 American Cyanamid Co Stable liquid preparations of 7-chlorotetracycline
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
SU432703A3 (ja) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер

Cited By (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198391A (en) * 1973-07-20 1980-04-15 R. P. Scherer Ltd. Pharmaceutical compositions
US4088750A (en) * 1974-02-22 1978-05-09 Burroughs Wellcome Co. Method and preparation for increasing bioavailability of digoxin
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4056610A (en) * 1975-04-09 1977-11-01 Minnesota Mining And Manufacturing Company Microcapsule insecticide composition
US4412986A (en) * 1977-06-07 1983-11-01 Yamanouchi Pharmaceutical Co. Ltd. Nifedipine-containing solid preparation composition
DE2822882A1 (de) * 1977-06-07 1978-12-21 Yamanouchi Pharma Co Ltd Nifedipine-enthaltende feste praeparatzusammensetzung, verfahren zu ihrer herstellung und ihre verwendung
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
WO1984003417A1 (en) * 1983-03-02 1984-09-13 Scherer Corp R P Soft gelatin capsules and fill achieving optimum hardness and flexibility during storage
US4780316A (en) * 1983-03-02 1988-10-25 R.P. Scherer Corporation Gelatin capsule
US4744988A (en) * 1983-03-02 1988-05-17 R. P. Scherer Corporation Soft gelatin capsules and methods for their production
AU567448B2 (en) * 1983-03-02 1987-11-19 R.P. Scherer Corporation Soft gelatin capsules and fill achieving optimum hardness and flexability during storage
US4537898A (en) * 1983-03-03 1985-08-27 Bayer Aktiengesellschaft Liquid formulations of dihydropyridines
US4777048A (en) * 1983-07-07 1988-10-11 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4832952A (en) * 1983-07-07 1989-05-23 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
EP0164587A3 (de) * 1984-05-23 1986-03-19 Bayer Ag Nifedipinpräparate und Verfahren zu ihrer Herstellung
EP0165450A3 (de) * 1984-05-23 1986-03-12 Bayer Ag Nifedipinkombinationspräparate und Verfahren zu ihrer Herstellung
EP0165450A2 (de) * 1984-05-23 1985-12-27 Bayer Ag Nifedipinkombinationspräparate und Verfahren zu ihrer Herstellung
EP0164587A2 (de) * 1984-05-23 1985-12-18 Bayer Ag Nifedipinpräparate und Verfahren zu ihrer Herstellung
US5266581A (en) * 1984-07-04 1993-11-30 Bayer Aktiengesellschaft Solid composition containing dihydropyridine, PVP and PVPP
AU584122B2 (en) * 1984-08-23 1989-05-18 Kuhlemann & Co. Metered dose aerosol of nifedipin
US4894235A (en) * 1984-10-23 1990-01-16 Dr. Rentschler, Arzneimmittel Gmbh & Co. Nifedipine-containing form of administration and method for its production
US4693892A (en) * 1985-09-10 1987-09-15 Bayer Aktiengesellschaft Gelatin containing β-carotene
US4857312A (en) * 1985-12-18 1989-08-15 Bayer Aktiengesellschaft Dihydropyridine spray, process for its preparation and its pharmaceutical use
US4689233A (en) * 1986-01-06 1987-08-25 Siegfried Aktiengesellschaft Coronary therapeutic agent in the form of soft gelatin capsules
US4976965A (en) * 1987-04-30 1990-12-11 Kali-Chemie Pharma Gmbh Coronary affecting medicinal composition
US5200192A (en) * 1987-11-11 1993-04-06 Walter Wimmer Instant oral-release capsule containing nifedipine
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5431916A (en) * 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5846563A (en) * 1993-09-09 1998-12-08 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US20040241233A1 (en) * 1993-09-09 2004-12-02 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems- amorphous drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6048548A (en) * 1993-09-09 2000-04-11 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems-amorphous drugs
US20060105035A1 (en) * 1993-09-09 2006-05-18 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6136343A (en) * 1993-09-09 2000-10-24 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6245356B1 (en) 1993-09-09 2001-06-12 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems-amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US20040234598A1 (en) * 1993-09-09 2004-11-25 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
WO1997038662A3 (en) * 1996-04-12 1998-02-12 Flemington Pharmaceutical Corp Buccal polar spray or capsule
WO1997038662A2 (en) * 1996-04-12 1997-10-23 Flemington Pharmaceutical Corporation Buccal polar spray or capsule
US6093420A (en) * 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US6689386B2 (en) 1996-07-08 2004-02-10 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US6245355B1 (en) 1996-07-08 2001-06-12 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US20040265239A1 (en) * 1997-10-01 2004-12-30 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20050025715A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20060222597A1 (en) * 1997-10-01 2006-10-05 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US6676931B2 (en) 1997-10-01 2004-01-13 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US20060216240A1 (en) * 1997-10-01 2006-09-28 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040062716A1 (en) * 1997-10-01 2004-04-01 Novadel Pharma Inc. Buccal, polar and non-polar spray of capsule
US9078816B2 (en) 1997-10-01 2015-07-14 Suda Ltd. Buccal, polar and non-polar spray containing ondansetron
US20040120896A1 (en) * 1997-10-01 2004-06-24 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US8236285B2 (en) 1997-10-01 2012-08-07 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20100092403A1 (en) * 1997-10-01 2010-04-15 Dugger Iii Harry A Buccal, polar and non-polar spray containing zolpidem
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20090162297A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing ondansetron
US20050025713A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050025712A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20070048229A1 (en) * 1997-10-01 2007-03-01 Novadel Pharma Inc. Buccal, polar and non-polar spray containing atropine
US20050025716A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050025717A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050025714A1 (en) * 1997-10-01 2005-02-03 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20060216241A1 (en) * 1997-10-01 2006-09-28 Novadel Pharma Inc. Buccal, polar and non-polar spray containing diazepam
US20090162298A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing sumatriptan
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20050142069A1 (en) * 1997-10-01 2005-06-30 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20090123387A1 (en) * 1997-10-01 2009-05-14 Dugger Iii Harry A Buccal, polar and non-polar spray or capsule containing cardiovascular or reneal drugs
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20090118170A1 (en) * 1997-10-01 2009-05-07 Dugger Iii Harry A Buccal, polar and non-polar spray or capsule
US6969508B2 (en) 1997-10-01 2005-11-29 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6977070B2 (en) 1997-10-01 2005-12-20 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281753A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6998110B2 (en) 1997-10-01 2006-02-14 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule
US20060210484A1 (en) * 1997-10-01 2006-09-21 Novadel Pharma Inc. Buccal, polar and non-polar spray containing testosterone
US20060159624A1 (en) * 1997-10-01 2006-07-20 Dugger Harry A Iii Buccal, polar and non-polar spray containing zolpidem
US20060165604A1 (en) * 1997-10-01 2006-07-27 Dugger Harry A Iii Buccal, polar and non-polar spray containing sumatriptan
US20060171896A1 (en) * 1997-10-01 2006-08-03 Dugger Harry A Iii Buccal, polar and non-polar spray containing alprazolam
US20060198790A1 (en) * 1997-10-01 2006-09-07 Dugger Harry A Iii Buccal, polar and non-polar spray containing ondansetron
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6875793B2 (en) 1997-10-15 2005-04-05 Penwest Pharmaceuticals Co. Once-a-day controlled release sulfonylurea formulation
US6537578B1 (en) 1997-10-15 2003-03-25 Penwest Pharmaceuticals Co. Once-a-day controlled release sulfonylurea formulation
US20030102246A1 (en) * 1999-03-20 2003-06-05 Lts Lohmann Therapie-Systeme Ag Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof
EP1208843A1 (en) * 1999-08-31 2002-05-29 Chugai Seiyaku Kabushiki Kaisha Soft capsules
US6893658B1 (en) 1999-08-31 2005-05-17 Chugai Seiyaku Kabushiki Kaisha Soft capsules
EP1208843A4 (en) * 1999-08-31 2002-09-11 Chugai Pharmaceutical Co Ltd SOFT CAPSULES
US20040170684A1 (en) * 1999-09-30 2004-09-02 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs
US8679535B2 (en) 1999-09-30 2014-03-25 Endo Pharmaceuticals Inc. Sustained release matrix systems for highly soluble drugs
US20070218137A1 (en) * 1999-09-30 2007-09-20 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs
WO2002087543A1 (en) * 2001-05-01 2002-11-07 Biozone Laboratories, Inc. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030003144A1 (en) * 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20050084457A1 (en) * 2001-06-01 2005-04-21 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20050169983A1 (en) * 2002-04-25 2005-08-04 Hassan Emadeldin M. Chewable soft capsule
US9072677B2 (en) 2002-04-25 2015-07-07 Banner Life Sciences Llc Chewable soft capsules
US9668976B2 (en) 2002-04-25 2017-06-06 Banner Life Sciences, LLC Chewable soft capsules
US8765174B2 (en) 2002-04-25 2014-07-01 Banner Pharmacaps Inc. Chewable soft capsule
US8097279B2 (en) 2002-04-25 2012-01-17 Banner Pharmacaps Inc. Chewable soft capsule
US9861586B2 (en) 2002-04-25 2018-01-09 Patheon Softgels, LLC Chewable soft capsules
US8414916B2 (en) 2002-04-25 2013-04-09 Banner Pharma Caps, Inc. Chewable soft capsule
US8241665B2 (en) 2002-04-25 2012-08-14 Banner Pharmacaps, Inc. Chewable soft capsule
US10342763B2 (en) 2002-04-25 2019-07-09 Patheon Softgels, Inc. Chewable soft capsules
EP1502588A1 (en) * 2002-05-09 2005-02-02 Chugai Seiyaku Kabushiki Kaisha Light-stabilized soft capsule for formulations
US20100021535A1 (en) * 2002-05-09 2010-01-28 Chugai Seiyaku Kabushiki Kaisha Light-stabilized soft capsule formulations
EP1502588A4 (en) * 2002-05-09 2011-05-04 Chugai Pharmaceutical Co Ltd FORMULATIONS OF PHOTOSTABILIZED MOLLE CAPSULES
US20050214361A1 (en) * 2002-05-09 2005-09-29 Chugai Seiyaku Kabushiki Kaisha Photostabilized soft capsule
US8703182B2 (en) 2002-05-09 2014-04-22 Chugai Seiyaku Kabushiki Kaisha Light-stabilized soft capsule formulations
CN101300010B (zh) * 2005-10-31 2012-06-06 兴和株式会社 光稳定性优异的医药制剂
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods
US20110040266A1 (en) * 2007-05-10 2011-02-17 Blondino Frank E Anti-insomnia compositions and methods
US20080280947A1 (en) * 2007-05-10 2008-11-13 Blondino Frank E Anti-insomnia compositions and methods
US20090107836A1 (en) * 2007-10-30 2009-04-30 Novellus Systems, Inc. Closed Contact Electroplating Cup Assembly
US20100286277A1 (en) * 2008-01-18 2010-11-11 Wurm David B Method to enhance aqueous solubility of poorly soluble actives
US8497303B2 (en) 2008-01-18 2013-07-30 Dow Global Technologies Llc Method to enhance aqueous solubility of poorly soluble actives
CN102300563A (zh) * 2009-01-29 2011-12-28 大日本住友制药株式会社 具有内核的口腔崩解片剂
US9205123B2 (en) 2010-02-23 2015-12-08 Tasly Pharmaceutical Group Co., Ltd. Capsule of compound danshen dripping pills
TWI571257B (zh) * 2011-02-23 2017-02-21 Tasly Pharmaceutical Group Co Capsule preparation
WO2019219693A1 (en) 2018-05-14 2019-11-21 Capsugel Belgium Nv Capsules with opacifier
EP3925602A1 (en) * 2018-05-14 2021-12-22 Capsugel Belgium NV Capsules with opacifier
US11517535B2 (en) 2018-05-14 2022-12-06 Capsugel Belgium Nv Capsules with opacifier
US11890383B2 (en) 2018-05-14 2024-02-06 Capsugel Belgium Nv Capsules with opacifier
WO2019241519A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition

Also Published As

Publication number Publication date
BG27728A3 (en) 1979-12-12
ES406047A1 (es) 1981-08-16
SU432703A3 (ja) 1974-06-15
MY7800003A (en) 1978-12-31
BE787951A (fr) 1973-02-26
DK130628C (ja) 1975-08-25
IL40165A0 (en) 1972-10-29
JPS5434048B2 (ja) 1979-10-24
DK130628B (da) 1975-03-17
JPS4828621A (ja) 1973-04-16
FR2150848B1 (ja) 1976-04-16
CA981582A (en) 1976-01-13
IE36891B1 (en) 1977-03-16
IL40165A (en) 1975-03-13
RO88521A (ro) 1987-04-30
DD99729A5 (ja) 1973-08-20
CY918A (en) 1977-12-23
JPS53121921A (en) 1978-10-24
KE2756A (en) 1977-10-14
NL7211565A (ja) 1973-02-27
NL176836C (nl) 1985-06-17
FR2150848A1 (ja) 1973-04-13
FI53922C (fi) 1979-09-07
IE36891L (en) 1973-02-24
GB1362627A (en) 1974-08-07
RO88521B (ro) 1987-05-01
HK44877A (en) 1977-09-09
LU65929A1 (ja) 1973-01-15
NL176836B (nl) 1985-01-16
NO138167C (no) 1978-07-26
FI53922B (fi) 1978-05-31
KR780000433B1 (en) 1978-10-14
SG34877G (en) 1987-04-03
EG10633A (en) 1976-08-31
NO138167B (no) 1978-04-10

Similar Documents

Publication Publication Date Title
US3784684A (en) Coronary dilator in a pharmaceutical dosage unit form
SU1544173A3 (ru) Способ получени сукральфата
CZ114093A3 (en) Sulfate of 3-£2-(dimethylamino)ethyl-n-methyl-1h-indole-5-methane sulfonamide, and pharmaceutical preparations containing thereof
WO1999062516A1 (en) A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer
NO840770L (no) Vaesketilbredninger av dihydropyridiner, en fremgangsmaate til deres fremstilling, samt deres anvendelse til bekjempelse av sykdommer
HUT45403A (en) Process for production of medical compositions with increased percutane penetrating ability
US3069321A (en) Choline salicylate composition and methods of use
EP0185210A2 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
US3621094A (en) Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
RU2143906C1 (ru) Применение диметикона для лечения афт и стоматита
GB2203044A (en) Nasal compositions
PT748222E (pt) Composicao antitussica contendo um antitussico e uma benzidamina
KR890004705A (ko) 항바이러스성 제제
DE2209526C3 (de) Coronartherapeutlkum in Form von Gelatine-BeiBkapseln
Leahey et al. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol
JPS58113126A (ja) 瞬間口中放出性舌下軟カプセル剤の製造方法
Chakravorty et al. Human anticancer effect of podophyllum derivatives (SPG and SPI): a preliminary report.
CZ243898A3 (cs) Vodná formulace bambuterolu a její použití
Jonkman et al. Variations in the bioavailability of thiazinamium methylsulfate
Chin et al. Use of physostigmine in tricyclic antidepressant poisoning
US2061557A (en) Anesthetic combinations containing, besides a local anesthetic agent, a vasoconstricting agent
ATE45090T1 (de) Pharmazeutische zusammensetzung in oralen darreichungsformen.
JPS60120811A (ja) 軟質ゼラチンカプセル
US2882200A (en) Composition comprising 3-methylpent-1-ene-4-yne-3-ol and process of inducing hypnosis therewith
EP0273253A2 (de) Verwendung von 6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo-[5,4-d]azepin zur Freisetzung von Wachstumshormon

Legal Events

Date Code Title Description
CC Certificate of correction